ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoantibodies"

  • Abstract Number: 3022 • 2016 ACR/ARHP Annual Meeting

    Autoantibodies to Peptidylarginine Deiminase 2 Protect Against Radiographic Progression in Patients with Rheumatoid Arthritis

    Erika Darrah1, Jon T. Giles2, Ryan Davis1, Pooja Naik1, Maximilian Konig1 and Felipe Andrade1, 1Department of Medicine, Division of Rheumatology, The Johns Hopkins University, Division of Rheumatology, Baltimore, MD, 2Columbia University, College of Physicians and Surgeons, Division of Rheumatology, New York, NY

    Background/Purpose:  The mechanisms that drive clinical heterogeneity and outcomes in patients with rheumatoid arthritis (RA) are poorly understood, but precise biomarkers may identify clinically unique…
  • Abstract Number: 274 • 2016 ACR/ARHP Annual Meeting

    Splicing Factor Proline/Glutamine-Rich Is a Novel Autoantigen of Dermatomyositis and Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody.

    Yuji Hosono1, Ran Nakashima1, Kosaku Murakami1, Yoshitaka Imura1, Satoshi Serada2, Minoru Fujimoto3, Hajime Yoshifuji1, Koichiro Ohmura4, Tetsuji Naka5 and Tsuneyo Mimori4, 1Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, 2Laboratory for Immune Signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan, 3Laboratry of immune signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan, 4Kyoto University Graduate School of Medicine, Kyoto, Japan, 5Laboratory for immune signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan

    Background/Purpose:   Anti- melanoma differentiation-associated gene 5 (MDA5) antibody positive dermatomyositis (DM) and clinically amyopathic DM (CADM) often develop rapidly progressive interstitial lung disesase (RP-ILD),…
  • Abstract Number: 989 • 2016 ACR/ARHP Annual Meeting

    A Randomized Controlled Trial of Rheumatoid Arthritis Risk Disclosure Personalized to Genetics, Autoantibodies, and Lifestyle Among Unaffected First-Degree Relatives: The Personalized Risk Estimator for RA (PRE-RA) Family Study

    Jeffrey A. Sparks1, Maura D. Iversen2, Zhi Yu3, Nellie A. Triedman3, Maria G. Prado3, Rachel Miller Kroouze4, Sarah S. Kalia5, Elinor A. Mody3, Simon M. Helfgott3, Derrick J. Todd3, Paul F. Dellaripa3, Bonnie L. Bermas3, Kevin D. Deane6, Karen H. Costenbader3, Bing Lu3, Robert C. Green5 and Elizabeth W. Karlson3, 1Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Physical Therapy, Movement and Rehabilitation Sciences, Northeastern University, Boston, MA, 3Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Division of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 6Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO

    Background/Purpose : Disclosure of genetic risk information alone has had limited impact on changing health behaviors in research trials. Prior studies have not evaluated whether…
  • Abstract Number: 2307 • 2016 ACR/ARHP Annual Meeting

    Influence of Season and Residential Environment on Development of Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis with Interstitial Lung Disease

    Naoshi Nishina1, Shinji Sato2, Yasushi Kawaguchi3, Atsushi Kawakami4, Maasa Tamura5, Kei Ikeda6, Takahiro Nunokawa7, Yoshinori Tanino8, Katsuaki Asakawa9, Yuko Kaneko10, Takahisa Gono11, Kenichi Masui12, Masataka Kuwana1 and JAMI investigators, 1Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, 3Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 4Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 5Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 6Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, 7Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, 8Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan, 9Division of Respiratory Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan, 10Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 11Department of Rheumatology, Jichi Medical University Saitama Medical Center, Saitama, Japan, 12Department of Anesthesiology, National Defense Medical College School of Medicine, Tokorozawa, Japan

    Background/Purpose: Environmental triggers such as infection are considered to be involved in pathogenesis of polymyositis (PM) and dermatomyositis (DM). This study was aimed to investigate…
  • Abstract Number: 3239 • 2016 ACR/ARHP Annual Meeting

    Expression of IFN-Regulated Genes in Autoantibody Exposed Babies in Utero

    Malin Hedlund1, Gudny-Ella Thorlacius1, Margarita Ivanchenko1, Vijole Ottosson1, Amina Ossoinak1, Linda Lagnefeldt1, Joanna Tingstrom1, Alexander Espinosa1, Lars Rönnblom2, Maija-Leena Eloranta2, Sven-Erik Sonesson1 and Marie Wahren-Herlenius3, 1Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Stockholm, Sweden, 2Uppsala University, Department of Medical Sciences, Rheumatology and Science for Life Laboratory, Uppsala, Sweden, 3Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden

    Background/Purpose: Ro/SSA autoantibodies and an IFN signature are commonly present in women with Sjögren’s syndrome and SLE. During pregnancy, the autoantibodies are transported across the…
  • Abstract Number: 281 • 2016 ACR/ARHP Annual Meeting

    Characterization of Anti-3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Autoantibodies in Juvenile Idiopathic Inflammatory Myopathies

    Takayuki Kishi1, Andrew Mammen2,3, Katherine Pak2, Lilliana Barillas-Arias4, Michael Henrickson5, Paul L. McCarthy6, Bracha Shaham7, Pamela F. Weiss8, Iren Horkayne-Szakaly9, Frederick W. Miller10, Lisa G. Rider10 and the Childhood Myositis Heterogeneity Study Group, 1Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 3Neurology and Medicine, Johns Hopkins University, Baltimore, MD, 4Bernard & Millie Duker Children's Hospital, Albany Medical Center, Albany, NY, 5Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 6Department of Pediatrics, Yale University School of Medicine, New Haven, CT, 7Pediatric Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, 8Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 9Joint Pathology Center, Defense Health Agency, Silver Spring, MD, 10Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD

    Background/Purpose:  Autoantibodies (Abs) to 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase (HMGCR) identified in adult myositis patients with immune-mediated necrotizing myopathies (IMNM) have been associated with severe weakness,…
  • Abstract Number: 1079 • 2016 ACR/ARHP Annual Meeting

    Discovery of Novel Autoantigens in Sjogren’s Syndrome with Potential for Subgrouping of Disease

    Peter Schulz-Knappe1, Petra Budde1, Hans-Dieter Zucht1, Heike Göhler1, Klaus Marquart1, Prof. Dr. Matthias Schneider2 and Torsten Witte3, 1Protagen AG, Dortmund, Germany, 2Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany, 3Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is a common autoimmune disease with exocrine gland dysfunction and multi-organ involvement. With the growing interest in conducting clinical trials…
  • Abstract Number: 2312 • 2016 ACR/ARHP Annual Meeting

    Anti-TIF1-Gamma Antibodies Are Not Associated with Other Paraneoplastic Rheumatic Syndromes Than Dermatomyositis

    Paulius Venalis1, Sandra Selickaja2,3, Karin Lundberg4, Rita Rugiene5,6 and Ingrid E. Lundberg7, 1Karolinska Institutet, Stockholm, Sweden, 2Vilnius University, Center of Rheumatology;, Vilnius, Lithuania, 3State Research Institute for Innovative Medicine, Vilnius, Lithuania, 4Rheumatology Unit, Department, Karolinska Institute, Stockholm, Sweden, 5Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania, 6State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania, 7Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: An association between cancer and dermatomyositis (DM), referred to as cancer-associated myositis, is well recognized and clinically important. The overall cancer risk is up…
  • Abstract Number: 15L • 2015 ACR/ARHP Annual Meeting

    Identification of Four-and-a-Half-LIM Domain 1 (FHL1) As a New Autoantibody Target in Idiopathic Inflammatory Myopathies

    Inka Albrecht1, Cecilia Wick1, Åsa Hallgren2, Anna Tjärnlund1, Kanneboyina Nagaraju3, Felipe Andrade4, Kathryn Thompson5, William Coley5, Aditi Phadke6, Lina-Marcela Diaz-Gallo1, Matteo Bottai7, Inger Nennesmo8, Karine Chemin9, Jessica Herrath10, Karin Johansson1, Anders Wikberg1, Jimmy Ytterberg1, Roman Zubarev1, Olof Danielsson11, Olga Krystufkova12, Jiri Vencovsky13, Nils Landegren2, Marie Wahren-Herlenius14, Leonid Padyukov15, Olle Kämpe2 and Ingrid E. Lundberg16, 1Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, 2Experimental Endocrinology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, 3The George Washington University Medical Center, Children's National Medical Center, Washington, DC, 4Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, 5Children's National Medical Center, Washington, DC, 6Research Center for Genetic Medicine, Children's National Medical Center, Washington, DC, 7Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 8Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden, 9Medicine, Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, 10Department of Medicine,, Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, 11Department of Clinical and Experimental Medicine, Division of Neurology, Faculty of Health Sciences, Linköping University, Linköping, Sweden, 12Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 13Rheumatology, Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 14Department of Medicine, Experimental Rheumatology Unit, Solna, Sweden, 15Department of medicine, Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, 16Karolinska University Hospital, Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of rare systemic autoimmune diseases collectively called myositis causing progressive muscle weakness. Interestingly, myositis-specific autoantibodies described…
  • Abstract Number: 966 • 2015 ACR/ARHP Annual Meeting

    In Rheumatoid Arthritis, Smoking Is Not Associated with Anti-Citrullinated Protein Antibodies per Se, but with the Concurrent Presence of Rheumatoid Factor, Anti-Citrullinated Protein Antibodies and Anti-Carbamylated Protein Antibodies

    Tineke van Wesemael1, Ammar Muhammad1, Sofia ajeganova2,3, Jennifer Humphreys4, Deborah P.M. Symmons5,6, Alex J Macgregor7, Ingiäld Hafström2, Leendert Trouw1, T. W. J. Huizinga1, Björn Svensson8, René E. M. Toes1, Suzanne M. Verstappen9 and Diane van der Woude1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Department of Medicine Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden, 3Rheumatology, Leiden University Medical Center, LEIDEN, Netherlands, 4Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit,, Manchester, United Kingdom, 5Centre for Musculoskeletal Research, University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, 6NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, 7Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom, 8Section of Rheumatology, Department of Clinical Sciences,, University of Lund, Lund, Sweden, 9Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom

    Background/Purpose : In rheumatoid arthritis (RA) a biological hypothesis has been proposed linking smoking with citrullination, the development of anti-citrulline autoimmunity and anti-citrullinated protein antibodies…
  • Abstract Number: 1859 • 2015 ACR/ARHP Annual Meeting

    Anti-Interferon Autoantibodies in Systemic Lupus Erythematosus Are Biologically Active and Have Distinct Functions

    Sarthak Gupta1,2, Ioanna P. Tatouli3, Lindsey B. Rosen1, Sarfaraz Hasni2, Illias Alevizos4, Zerai G. Manna2, Juan Rivera2, Chao Jiang2,5, Richard M. Siegel6, Steven M. Holland1, Haralampos M. Moutsopoulos3 and Sarah K. Browne1,7, 1Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 3Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, 4National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, 5National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD, 6NIAMS, Immunoregulation Section, Autoimmunity Branch, Bethesda, MD, 7Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD

    Background/Purpose: Anticytokine autoantibodies are pathogenic in many hematologic, pulmonary and infectious diseases. However, a systematic investigation of their presence and significance in autoimmune diseases is…
  • Abstract Number: 2602 • 2015 ACR/ARHP Annual Meeting

    CCP Antibody Negativity Is Associated with Higher Fatigue in Rheumatoid Arthritis

    Laura Cappelli1, Susan J. Bartlett2,3, Michelle Jones4 and Clifton Bingham4, 1Ste 4500, Johns Hopkins University, Baltimore, MD, 2Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, 3Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, 4Johns Hopkins University, Baltimore, MD

    Background/Purpose:   Fatigue in rheumatoid arthritis (RA) is common and highly debilitating. Emerging evidence suggests that seronegative RA patients differ from their seropositive peers in…
  • Abstract Number: 1016 • 2015 ACR/ARHP Annual Meeting

    Collagen Antibodies Induce Pain-like Behavior in Mice Independent of Inflammation and Complement Activation but Requires Fcγrs

    Gustaf Wigerblad1, Katalin Sandor1, Kutty Selva Nandakumar2, Rikard Holmdahl3 and Camilla Svensson1, 1Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, 2Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden, 3Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Collagen Antibody Induced Arthritis (CAIA) is an acute mouse model of rheumatoid arthritis (RA). It is induced by an intravenous injection of a cocktail…
  • Abstract Number: 1860 • 2015 ACR/ARHP Annual Meeting

    Autoantibodies Utilizing the Immunoglobulin Heavy Chain Variable Region Gene 4-34 (VH4-34) Exhibit Autoreactivity Towards, and Potential Competition with Galectins within Systemic Lupus Erythematosus (SLE)

    Kevin Cashman1, Asiya Chida2 and Ignacio Sanz2, 1Department of Medicine- Division of Rheumatology, Emory University, Atlanta, GA, 2Medicine, Emory University, Atlanta, GA

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by the propagation of autoreactive B cell populations leading to the production of pathogenic antibodies…
  • Abstract Number: 2698 • 2015 ACR/ARHP Annual Meeting

    Follicular Helper T Cells in Peripheral Blood of Patients with Rheumatoid Arthritis

    Alicia Beatriz Costantino1, Laura Onetti2, Melina del Valle Cloquell3, Cristina del Valle Acosta1, Eduardo Mussano2, Isaac Ignacio Cadile2, Cecilia María Rodriguez3, Stefania Santo1 and Paola Virginia Ferrero1, 1Córdoba, Laboratorio de Inmunología. Hospital Nacional de Clínicas. Facultad de Ciencias Médicas. Universidad Nacional de Córdoba, Córdoba, Argentina, 2Córdoba, Servicio de Reumatología. Hospital Nacional de Clínicas. Facultad de Ciencias Médicas. Universidad Nacional de Córdoba, Córdoba, Argentina, 3Córdoba, Laboratorio de Oncohematología, Hospital Nacional de Clínicas, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina

    Background/Purpose: RA is an autoimmune, inflammatory and chronic disease which aetiology is unknown. It presents different autoantibodies such as RF and ACPA. A population of…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology